接受血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂治疗的结节病患者死亡率与健康结局
本研究基于TriNetX研究网络数据库开展大型多中心调查,纳入诊断为结节病并接受ACEI或ARB处方的患者,所有队列对重要协变量进行匹配,评估结节病诊断后的死亡率、心脏和呼吸结局及脓毒症发生率。结果观察到,与ARB治疗患者相比,接受ACEI治疗的结节病患者死亡风险增加,心脏和呼吸结局更差,脓毒症发生率更高。作者认为ACEI与ARB在结节病患者中对结局的影响存在差异,提示RAAS信号在该病中可能具有致病作用,并强调为结节病患者谨慎选择RAAS调节剂的重要性。
要点
- 在结节病患者中,使用ACEI者较使用ARB者死亡风险增加。
- 使用ACEI的结节病患者心脏结局较ARB队列更差。
- 使用ACEI的结节病患者呼吸结局较ARB队列更差。
- 使用ACEI的结节病患者脓毒症发生率较ARB队列升高。
- 作者认为ACEI与ARB对结节病结局影响存在差异,强调谨慎选择RAAS调节剂。
适用人群与场景
- 诊断为结节病并接受ACEI或ARB处方的患者。
研究设计与关键结果
- 研究类型:基于TriNetX研究网络数据库的大型多中心调查;人群:诊断为结节病并接受ACEI或ARB处方的患者;所有队列对重要协变量进行匹配;评估结局包括结节病诊断后死亡率、心脏和呼吸结局及脓毒症发生率。
- 与ARB治疗患者相比,接受ACEI治疗的结节病患者死亡风险增加。
- 与ARB队列相比,接受ACEI治疗的结节病患者心脏结局更差。
- 与ARB队列相比,接受ACEI治疗的结节病患者呼吸结局更差。
- 与ARB队列相比,接受ACEI治疗的结节病患者脓毒症发生率更高。
证据类型、等级与局限
- 证据类型:基于TriNetX研究网络数据库的多中心调查。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,ACEI与ARB在结节病患者中对结局的影响存在差异,强调为结节病患者谨慎选择RAAS调节剂的重要性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sarcoidosis is a multisystem inflammatory disease in which management and outcomes can vary widely. The renin-angiotensin-aldosterone system (RAAS) has been implicated in its pathogenesis, yet the impact of RAAS modulators on health outcomes in sarcoidosis remains poorly understood.
RESEARCH QUESTION: How do pharmacologic modulators of RAAS affect health outcomes in patients with a diagnosis of sarcoidosis?
STUDY DESIGN AND METHODS: We conducted a large multicenter investigation using the TriNetX Research Network database. Patients included in this study were individuals with a diagnosis of sarcoidosis who were prescribed either an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB). All cohorts were matched for important covariates, and outcomes measured included mortality, cardiac and respiratory outcomes, and sepsis rates after sarcoidosis diagnosis.
RESULTS: We observed an increased mortality risk among patients with sarcoidosis prescribed ACEIs compared with patients prescribed ARB therapies. Furthermore, patients with sarcoidosis prescribed ACEIs showed worse cardiac and respiratory outcomes and increased sepsis rates compared with the ARB cohort.
INTERPRETATION: Our findings suggest that ACEIs and ARBs have divergent effects on outcomes in patients with sarcoidosis. These findings highlight the potential pathogenic role of RAAS signaling in this disease and underscore the importance of carefully selecting RAAS modulators for individuals with sarcoidosis.
参考来源
- Fares J, El Fadel O, Zhao J, et al. Mortality and Health Outcomes Among Patients With Sarcoidosis Treated With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Chest. 2024. PMID: 39313185. doi:10.1016/j.chest.2024.09.009
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。